Bioject Board Authorizes Redemption of all Series A Preferred

                     Stock  
Notice of Intent to Convert From Preferred Shareholder Enables Full Redemption  
  PORTLAND, Ore., Oct. 19 /PRNewswire/ -- 
Bioject Medical Technologies Inc. (Nasdaq: BJCT), a leading developer of 
needle-free drug delivery systems, today announced that its board of directors 
has approved the redemption of all outstanding shares of its Series A 
Convertible Preferred Stock for approximately $14.5 million.  The Series A 
Preferred shares are held by Elan Pharmaceutical Investments, Ltd. (Elan). 
Elan gave Bioject notice of Elan's intent to convert the Series A shares into 
Bioject common stock at an unspecified future time.  Bioject has until 
December 31, 2001 to give Elan a binding notice of redemption.  
Elan's notice followed Bioject's previously announced notice of redemption 
of a portion of the Series A shares held by Elan, pursuant to alternate 
redemption rights as stated in the company's articles of incorporation.  
The Series A Preferred Stock accrues dividends at an annual rate of 
9 percent and the Preferred Stock and all accrued dividends automatically 
convert to Bioject common stock in 2004 at a conversion price of $7.50 a 
share.  Accordingly, the practical effect of the planned redemption will be 
the repurchase by Bioject of approximately 1.95 million common equivalent 
shares for $7.50 a share.  
To finance all or part of the planned redemption of Elan's Series A 
shares, Bioject's board of directors also authorized the private placement of 
up to 2,000,000 shares of common stock and the calling of a special meeting of 
shareholders for the purpose of approving the issuance of common stock.  It is 
currently anticipated that the combined effect of the redemption of the Series 
A Preferred Stock and the proposed private placement will generate additional 
cash for the company and will not be dilutive to existing stockholders.  
"Elan's action in giving notice of intent to convert its Series A shares 
has created an excellent opportunity for the company," said Jim O'Shea, 
chairman, president and chief executive officer of Bioject.  "Redemption of 
all of the Series A shares will eliminate future earnings charges for dividend 
accruals, simplify our capital structure, and reduce Elan's beneficial 
ownership position by over 40%."  
In connection with Bioject's previous notice of partial redemption of 
Elan's Series A shares, Bioject filed a lawsuit in U.S. District Court in 
Oregon seeking an injunction to compel Elan to abide by the redemption 
provisions in Bioject's articles of incorporation.  Portions of Elan's October 
10 letter to Bioject suggest that Elan may dispute Bioject's right to 
partially redeem the Series A shares.  Bioject will continue to take all 
appropriate legal action to enforce its redemption rights, if necessary.  
About Bioject Medial Technologies:  Bioject Medical Technologies Inc., 
based in Portland, Oregon, is an innovative developer and manufacturer of 
needle-free drug delivery systems.  Needle-free injection works by forcing 
medication at high speed through a tiny orifice held against the skin.  This 
creates a fine stream of high-pressure fluid penetrating the skin and 
depositing medication in the tissue beneath.  The company is focused on 
developing mutually beneficial agreements with leading pharmaceutical and 
biotechnology companies.  Bioject's partners now include Amgen, Serono and 
Alkermes.  
This press release contains forward-looking statements within the meaning 
of the Private Securities Litigation Reform Act of 1995.  Such forward-looking 
statements involve known and unknown risks, uncertainties and other factors 
which may cause the actual results, performance or achievements of the 
company, or industry results, to be materially different from any future 
results, performance, or achievements expressed or implied by such 
forward-looking statements.  Readers of this press release are referred to the 
company's filings with the Securities and Exchange Commission, including the 
company's Annual Report on Form 10-K and Form 10-Q for further discussions of 
factors which could affect future results.  Forward-looking statements are 
based on the estimates and opinions of management on the date the statements 
are made.  The company assumes no obligation to update forward-looking 
statements if conditions or management's estimates or opinions should change.  
More information can be found at Bioject's home page at: 
http://www.bioject.com .  
                   MAKE YOUR OPINION COUNT - Click Here  
           http://tbutton.prnewswire.com/prn/11690X54037153 
  

SOURCE  Bioject Medical Technologies, Inc.  
-0-                             10/19/2001  
/CONTACT:  Jim O'Shea, Chairman, President & CEO, or John Gandolfo, Chief 
Financial Officer, +1-503-639-7221, both of Bioject Medical Technologies, 
Inc.; or Jim Flanagan of IR Strategic Advisors, +1-781-863-1333, or 
jflanagan@iradvisors.com, for Bioject Medical Technologies, Inc/  


    /Company News On-Call:  http://www.prnewswire.com/comp/101750.html / 
    /Web site:  http://www.bioject.com/ 


(BJCT)  
CO:  Bioject Medical Technologies, Inc.; Elan Pharmaceutical Investments, Ltd. 
ST:  Oregon 
IN:  MTC CPR 
SU:  SRP  
-0- Oct/19/2001 11:02 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.